1. Home
  2. IEP vs RYTM Comparison

IEP vs RYTM Comparison

Compare IEP & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IEP
  • RYTM
  • Stock Information
  • Founded
  • IEP 1987
  • RYTM 2008
  • Country
  • IEP United States
  • RYTM United States
  • Employees
  • IEP N/A
  • RYTM N/A
  • Industry
  • IEP Auto Parts:O.E.M.
  • RYTM Biotechnology: Pharmaceutical Preparations
  • Sector
  • IEP Consumer Discretionary
  • RYTM Health Care
  • Exchange
  • IEP Nasdaq
  • RYTM Nasdaq
  • Market Cap
  • IEP 4.6B
  • RYTM 3.8B
  • IPO Year
  • IEP 1987
  • RYTM 2017
  • Fundamental
  • Price
  • IEP $8.54
  • RYTM $61.74
  • Analyst Decision
  • IEP
  • RYTM Strong Buy
  • Analyst Count
  • IEP 0
  • RYTM 12
  • Target Price
  • IEP N/A
  • RYTM $74.92
  • AVG Volume (30 Days)
  • IEP 732.8K
  • RYTM 940.6K
  • Earning Date
  • IEP 05-07-2025
  • RYTM 05-06-2025
  • Dividend Yield
  • IEP 23.42%
  • RYTM N/A
  • EPS Growth
  • IEP N/A
  • RYTM N/A
  • EPS
  • IEP N/A
  • RYTM N/A
  • Revenue
  • IEP $10,025,000,000.00
  • RYTM $130,126,000.00
  • Revenue This Year
  • IEP N/A
  • RYTM $43.84
  • Revenue Next Year
  • IEP $5.82
  • RYTM $65.62
  • P/E Ratio
  • IEP N/A
  • RYTM N/A
  • Revenue Growth
  • IEP N/A
  • RYTM 68.06
  • 52 Week Low
  • IEP $7.27
  • RYTM $35.17
  • 52 Week High
  • IEP $19.10
  • RYTM $68.58
  • Technical
  • Relative Strength Index (RSI)
  • IEP 44.49
  • RYTM 61.94
  • Support Level
  • IEP $7.60
  • RYTM $59.54
  • Resistance Level
  • IEP $8.50
  • RYTM $62.83
  • Average True Range (ATR)
  • IEP 0.44
  • RYTM 4.27
  • MACD
  • IEP 0.02
  • RYTM 1.00
  • Stochastic Oscillator
  • IEP 67.55
  • RYTM 92.04

About IEP Icahn Enterprises L.P.

Icahn Enterprises LP is a provider of diversified business services in the United States. The company operates its business through varied segments which include Investment, Automotive, Energy, Food Packaging, Real Estate, Pharma, and Home Fashion. Among these, the Energy segment derives the maximum revenue from the company. Geographically, it generates maximum revenue from the United States.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Share on Social Networks: